NCT01179581View on ClinicalTrials.gov

First-in-Human Single Ascending and Multiple Dose of GLPG0634

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Healthy
Interventions
DRUG

GLPG0634

single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)

DRUG

placebo

single dose, oral solution or capsule (matching corresponding study medication)

DRUG

GLPG0634

multiple dose, capsule, 10 days

DRUG

placebo

multiple dose, capsule, 10 days

Trial Locations (1)

Unknown

SGS Stuivenberg, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY